Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-centric, Randomized, Double-blind, Parallel, Saline Controlled Phase II Safety and Efficacy study of PMZ-2010 as a resuscitative agent for Hypovolemic Shock due to excessive blood loss to be used along with standard shock treatment

Trial Profile

A Prospective, Multi-centric, Randomized, Double-blind, Parallel, Saline Controlled Phase II Safety and Efficacy study of PMZ-2010 as a resuscitative agent for Hypovolemic Shock due to excessive blood loss to be used along with standard shock treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Centhaquin (Primary)
  • Indications Hypovolaemic shock
  • Focus Adverse reactions
  • Sponsors Pharmazz
  • Most Recent Events

    • 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
    • 12 Nov 2018 Results (N=50) presented in a Pharmazz Media Release.
    • 12 Nov 2018 According to a Pharmazz media release, were presented in the Drug Discovery-Heart Failure Oral Abstracts Session II at the American Heart Association Scientific Sessions 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top